Merck Discontinues Two More Phase III Keytruda Studies

 
• By Joseph Haas
  
Pembrolizumab
Merck said it is giving up on two Phase III label-expansion studies for Keytruda • Source: Shutterstock

More from Immuno-oncology

More from Anticancer